Retrophin Hits Shkreli With $65m Lawsuit

When Retrophin ousted its high-profile founder Martin Shkreli in October, the company didn't reveal why it had chosen to change management. Now those reasons are front and center as the biotech files suit against the former CEO, alleging a wide variety of misconduct.

The four-year-old biotech is accusing Shkreli of not only shirking his "duty of loyalty" to Retrophin, but using company funds...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Archive

More from Scrip